Pancreatic Cancer

Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Lung, Other Urinary, Pancreas, Phase I, Urinary BladderA Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors
Colon, Esophagus, Liver, PancreasA Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal CancersPrincipal Investigator: Raghav Sundar
PancreasA Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma
Anus, Bones and Joints, Breast, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, ThyroidPROgram to address psychosocial Support, clinical outcomes, and genomic insights for Patients with EaRly onset cancers
Other Endocrine System, PancreasRandomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine TumorsPrincipal Investigator: Pamela L. Kunz